Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T + CD19 CAR-DC
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T + CD19 CAR-DC is a combination cell therapy comprising two distinct autologous cellular products engineered to target the B-cell antigen CD19. The first component, CD19 CAR-T, consists of T lymphocytes genetically modified to express a chimeric antigen receptor (CAR) specific for the surface protein CD19, which is highly expressed on B-cell malignancies. These engineered T cells recognize and kill malignant and normal B cells expressing CD19 through MHC-unrestricted mechanisms involving cytolytic granule release (perforin/granzyme), Fas/FasL-mediated apoptosis, and cytokine secretion[2][4][6]. The second component, CD19 CAR-DC, refers to dendritic cells (DCs) that are also genetically modified with a similar or identical anti-CD19 chimeric antigen receptor. While less common than T cell-based approaches, dendritic cell-based therapies can enhance antitumor immunity by presenting tumor antigens more effectively and activating endogenous immune responses[6]. This dual approach aims to leverage both direct cytotoxicity from the T cells and enhanced immune activation from the dendritic cells for improved efficacy against relapsed or refractory B-cell malignancies.
- Other names
- CD19 CAR-T + CD19 CAR-DC
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T + CD19 CAR-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T + CD19 CAR-DC.